Cell Therapy News

The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.

Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.

AI could have the ability to answer some patient questions on cancer instead of clinicians, reducing clinician burdens and improving access to care, according to study results published in JAMA Oncology.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.

A phase 1 trial showed chimeric antigen receptor T-cell therapy may hold promise for the treatment of glioblastoma.

As part of routine screening for financial hardship, clinicians should discuss an individual’s employment, access to paid leave and health insurance coverage when constructing a treatment plan relating to cancer care.

Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.

In this episode, host Shikha Jain, MD, speaks with Sean Bohen, MD, about how cancer therapies are changing how oncology can be discussed, shifting from clinical to industry work and more.

New guidelines for vaccinating adults with solid or hematologic cancers detailed the importance of vaccination optimization, multidisciplinary coordination and vaccination of household members.

A sequential chimeric antigen receptor T-cell therapy and haploidentical hematopoietic stem cell transplantation strategy conferred remissions in certain patients with relapsed or refractory CD7-positive hematologic cancers.